BACKGROUND: Prophylactic dissection facilitates identification of central lymph node (LN) metastasis in patients with papillary thyroid cancer (PTC). Because most staging systems do not stratify risks by the number of LN metastases, postoperative treatments vary among different institutions. Therefore we investigated the significance of number of LN metastases in risk stratification for recurrence in PTC. MATERIAL AND METHODS: A retrospective review was performed for 3,305 patients who had undergone thyroidectomy at Ajou University Hospital. A total of 2,462 patients (73.5 %) underwent total thyroidectomy, and another 3,152 (94.1 %) underwent central LN dissection. Lateral cervical LN dissection had been performed in 420 patients (12.5 %). RESULTS: There were 115 patients with recurrence (3.4 %). Recurrence-free rates were 94.6 % at 5 years and 89.4 % at 10 years. On univariate analysis, prognostic factors for recurrence were extent of thyroidectomy, tumor size, capsular invasion, T stage, N stage, number of LN metastasis, TNM stage, and radioactive iodine (RAI) therapy. On multivariate analysis, number of LN metastasis and N stage were significant prognostic factors for recurrence. Recurrence-free rate was significantly different between patients with 0-1 LN and those with 2 or more LN. CONCLUSIONS: Number of metastatic LN was a significant prognostic factor, in addition to the N stage. Therefore, number of metastatic LN must be considered for postoperative staging system to tailor treatment and follow-up recommendations. In addition, patients with ≥2 metastatic LN may benefit from total thyroidectomy and RAI therapy with postoperative follow-up with serum thyroglobulin.
BACKGROUND: Prophylactic dissection facilitates identification of central lymph node (LN) metastasis in patients with papillary thyroid cancer (PTC). Because most staging systems do not stratify risks by the number of LN metastases, postoperative treatments vary among different institutions. Therefore we investigated the significance of number of LN metastases in risk stratification for recurrence in PTC. MATERIAL AND METHODS: A retrospective review was performed for 3,305 patients who had undergone thyroidectomy at Ajou University Hospital. A total of 2,462 patients (73.5 %) underwent total thyroidectomy, and another 3,152 (94.1 %) underwent central LN dissection. Lateral cervical LN dissection had been performed in 420 patients (12.5 %). RESULTS: There were 115 patients with recurrence (3.4 %). Recurrence-free rates were 94.6 % at 5 years and 89.4 % at 10 years. On univariate analysis, prognostic factors for recurrence were extent of thyroidectomy, tumor size, capsular invasion, T stage, N stage, number of LN metastasis, TNM stage, and radioactive iodine (RAI) therapy. On multivariate analysis, number of LN metastasis and N stage were significant prognostic factors for recurrence. Recurrence-free rate was significantly different between patients with 0-1 LN and those with 2 or more LN. CONCLUSIONS: Number of metastatic LN was a significant prognostic factor, in addition to the N stage. Therefore, number of metastatic LN must be considered for postoperative staging system to tailor treatment and follow-up recommendations. In addition, patients with ≥2 metastatic LN may benefit from total thyroidectomy and RAI therapy with postoperative follow-up with serum thyroglobulin.
Authors: F Pattou; F Combemale; S Fabre; B Carnaille; M Decoulx; J L Wemeau; A Racadot; C Proye Journal: World J Surg Date: 1998-07 Impact factor: 3.352
Authors: Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger Journal: J Clin Endocrinol Metab Date: 2005-07-19 Impact factor: 5.958
Authors: P E Goretzki; D Simon; A Frilling; J Witte; C Reiners; M Grussendorf; F A Horster; H D Röher Journal: Br J Surg Date: 1993-08 Impact factor: 6.939
Authors: Stéphane Bonnet; Dana Hartl; Sophie Leboulleux; Eric Baudin; Jean D Lumbroso; Abir Al Ghuzlan; Linda Chami; Martin Schlumberger; Jean Paul Travagli Journal: J Clin Endocrinol Metab Date: 2008-12-30 Impact factor: 5.958
Authors: C F A Eustatia-Rutten; J W A Smit; J A Romijn; E P M van der Kleij-Corssmit; A M Pereira; M P Stokkel; J Kievit Journal: Clin Endocrinol (Oxf) Date: 2004-07 Impact factor: 3.478
Authors: Laura Y Wang; Frank L Palmer; Iain J Nixon; R Michael Tuttle; Jatin P Shah; Snehal G Patel; Ashok R Shaha; Ian Ganly Journal: Ann Surg Oncol Date: 2015-02-10 Impact factor: 5.344
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Jialing Zhang; Clara L Feider; Chandandeep Nagi; Wendong Yu; Stacey A Carter; James Suliburk; Hop S Tran Cao; Livia S Eberlin Journal: J Am Soc Mass Spectrom Date: 2017-02-28 Impact factor: 3.109
Authors: G Sapuppo; F Palermo; M Russo; M Tavarelli; R Masucci; S Squatrito; R Vigneri; G Pellegriti Journal: J Endocrinol Invest Date: 2017-06-23 Impact factor: 4.256
Authors: Ji Min Na; Dong Chul Kim; Dae Hyun Song; Hyo Jung An; Hyun Min Koh; Jeong-Hee Lee; Jong Sil Lee; Jung Wook Yang; Min Hye Kim Journal: J Pathol Transl Med Date: 2022-05-11